Perspectives From the Frontier of Life Sciences

Points of view on partnerships, market access, advanced therapies and the GCC opportunity, written for leaders who have to act on them.

Featured · LinkedIn Article

“A breakthrough therapy is only the beginning.”

Dr. Vivek Vikram Singh · Founder & MD

Biopharma Growth · Partnerships

From Asset Hunting to Ecosystem Building: The New Playbook for Biopharma Growth

Developing a breakthrough therapy is only the first step. Success in biopharma will increasingly belong to those who get innovation to patients through partnerships, scalable manufacturing, market-access strategy and local execution.

The article looks at what this means for cell and gene therapy, and at the growing influence of the GCC, India and China in shaping where and how new medicines reach patients.

Cell & gene therapyPartnershipsMarket accessGCC

Read on LinkedIn →

Latest on LinkedIn

Recent Perspectives

Sep 2026 · Post

Life After BCMA: Is GPRC5D Myeloma’s Next Big Market?

BMS’s arlo-cel hits its registrational Phase 2 endpoints. With bispecifics and dual-target CAR-Ts in the mix, treatment sequencing, not just reimbursement, may decide the winners.

Multiple myelomaCAR-T

Read on LinkedIn →

Aug 2026 · Post

The $3.5B Bet on Hitting “Reset” on the Immune System

J&J’s deal with Sail Biomedicines puts in vivo CAR-T on the autoimmune map: no ex vivo manufacturing, no lymphodepletion. Now durability, repeat dosing and safety take centre stage.

In vivo CAR-TAutoimmunity

Read on LinkedIn →

Aug 2026 · Article

Off-the-Shelf CAR-T Faces Its Moment of Truth

FDA RMAT for cema-cel as first-line consolidation in MRD-positive lymphoma. Early MRD clearance looks striking (58% vs 17%), but the 2027–28 event-free survival readouts will decide adoption.

Allogeneic CAR-TRegulatory

Read on LinkedIn →

Follow Dr. Singh on LinkedIn for new perspectives →

Want to Discuss This for Your Portfolio?

We turn perspectives like these into strategies for specific assets and markets.

Start a Conversation